PKI - PerkinElmer, Inc.
| Previous close | 95.85 |
| Open | 95.89 |
| Bid | 25.96 x 800 |
| Ask | 94.48 x 1000 |
| Day's range | 94.18 - 96.17 |
| 52-week range | 71.83 - 103.00 |
| Volume | 564,466 |
| Avg. volume | 645,371 |
| Market cap | 10B |
| Beta (5Y Monthly) | 1.30 |
| PE ratio (TTM) | 44.99 |
| EPS (TTM) | 2.10 |
| Earnings date | 29 Jan 2020 - 3 Feb 2020 |
| Forward dividend & yield | 0.28 (0.29%) |
| Ex-dividend date | 2020-01-16 |
| 1y target est | 95.85 |
- Business Wire
PerkinElmer Launches First FDA-Approved Assay Kit to Screen for Duchenne Muscular Dystrophy in Newborns
PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug Administration (FDA) approval. This solution is the first commercially available assay for screening newborns affected by Duchenne muscular dystrophy (DMD).
- Simply Wall St.
Announcing: PerkinElmer (NYSE:PKI) Stock Increased An Energizing 126% In The Last Five Years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
- Zacks
Here's Why You Should Hold on to PerkinElmer Stock for Now
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
- Simply Wall St.
Should You Be Tempted To Sell PerkinElmer, Inc. (NYSE:PKI) Because Of Its P/E Ratio?
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
- Zacks
PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss
PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
- Zacks
PerkinElmer (PKI) Tops Q3 Earnings Estimates
PerkinElmer (PKI) delivered earnings and revenue surprises of 4.95% and -2.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
PerkinElmer (PKI) to Report Q3 Earnings: What's in Store?
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q3 earnings. However, forex is likely to have been a dampener.
- Zacks
PerkinElmer (PKI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Should PerkinElmer, Inc. (NYSE:PKI) Focus On Improving This Fundamental Metric?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Zacks
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
- Zacks
Bruker To Buy Freiberg Instruments' Magnettech EPR Business
The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.
- Simply Wall St.
Is It Too Late To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?
PerkinElmer, Inc. (NYSE:PKI), which is in the life sciences business, and is based in United States, saw significant...
- Simply Wall St.
Did PerkinElmer, Inc. (NYSE:PKI) Insiders Sell Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Zacks
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
- Zacks
Why Is PerkinElmer (PKI) Down 8.4% Since Last Earnings Report?
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Scientific Instruments Industry Outlook: Prospects Look Good
Scientific Instruments Industry Outlook: Prospects Look Good
- Simply Wall St.
PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
- Zacks
PerkinElmer (PKI) Q2 Earnings and Revenues Miss Estimates
Higher revenues and growth in Diagnostics segment benefit PerkinElmer's (PKI) Q2 earnings. However, forex remains a woe.
Motley FoolPerkinElmer Inc (PKI) Q2 2019 Earnings Call Transcript
PKI earnings call for the period ending June 30, 2019.
- Zacks
PerkinElmer (PKI) Misses Q2 Earnings and Revenue Estimates
PerkinElmer (PKI) delivered earnings and revenue surprises of -0.99% and -1.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Estimating The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)
In this article we are going to estimate the intrinsic value of PerkinElmer, Inc. (NYSE:PKI) by taking the foreast...
- Zacks
What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?
Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.
- Simply Wall St.
Does PerkinElmer, Inc.'s (NYSE:PKI) CEO Pay Compare Well With Peers?
Rob Friel has been the CEO of PerkinElmer, Inc. (NYSE:PKI) since 2008. This analysis aims first to contrast CEO...
- Zacks
Here's Why You Should Hold PerkinElmer (PKI) Stock for Now
PerkinElmer (PKI) raises earnings per share guidance for 2019.
